Eif5a2-KO Mouse
一般名
Eif5a2-KO
製品ID
S-KO-17917
背景情報
C57BL/6JCya
系統ID
KOCMP-208691-Eif5a2-B6J-VB
状況
このマウス系統を論文で使用する場合は、「Eif5a2-KO Mouse(カタログ番号S-KO-17917)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Eif5a2-KO
系統ID
KOCMP-208691-Eif5a2-B6J-VB
遺伝子名
製品ID
S-KO-17917
遺伝子別名
eIF5AII, 9630038B20
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 3
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000060500
NCBIトランスクリプトID
NM_177586
ターゲット領域
Exon 2~3
有効領域の大きさ
~2.1 kb
遺伝子研究の概要
Eif5a2, the eukaryotic initiation factor 5A2 gene, is a highly conserved and multifunctional gene. It significantly influences various cellular processes such as translation elongation, RNA binding, ribosome binding, protein binding, and post-translational modifications. It is involved in multiple molecular pathways, with its overexpression frequently observed in multiple cancers where it functions as an oncoprotein, and also implicated in drug resistance [1].
Eif5a2-related functional studies show that its knockdown in various cancer cell lines leads to significant impacts. In intrahepatic cholangiocarcinoma cells, high levels of Eif5a2 promote cell proliferation, migration, and invasion by activating the PI3K/AKT/mTOR signaling pathway [2]. In epithelial ovarian cancer cells, knockdown of Eif5a2 reduces the expression of stem-related markers, inhibits self-renewal ability, improves chemosensitivity, and inhibits tumorigenesis in vivo, indicating its positive regulation of stemness via the E2F1/KLF4 pathway [3]. In cervical cancer cells, Eif5a2 knockdown inhibits cell proliferation, migration, and invasion, promotes apoptosis, and enhances cisplatin sensitivity, with its effect mediated through AGR2 [4]. In bladder cancer cells, Eif5a2 promotes doxorubicin resistance through the TGF-β signaling pathway, and its knockdown reverses this effect [5]. In ovarian cancer, knockout of Eif5a2 inhibits epithelial-to-mesenchymal transition (EMT), cell migration, invasion, tumor growth, and metastasis, while overexpression promotes these processes by activating the TGFβ pathway [6]. In oral cancer SCC-9 cells, targeting Eif5a2 reduces invasion and migration, promotes apoptosis, increases chemosensitivity, and upregulates Bim and E-cadherin [7]. In anaplastic thyroid carcinoma, targeting Eif5a2 with shRNA induces cell death in vitro and in vivo, downregulating p-Smad2/3, while overexpression promotes cell growth and upregulates p-Smad3 [8].
In conclusion, Eif5a2 is a crucial gene involved in multiple cellular regulatory processes and plays a significant role in tumorigenesis and drug resistance in various cancers. Gene knockout and knockdown models in cancer cell lines and in vivo mouse models have revealed its functions in promoting cancer cell proliferation, invasion, metastasis, stemness, and drug resistance through different signaling pathways, providing potential therapeutic targets for cancer treatment.
References:
1. Xiong, Xifeng, Du, Yanli, Liu, Peng, Miao, Haixiong, Ning, Bo. 2025. Unveiling EIF5A2: A multifaceted player in cellular regulation, tumorigenesis and drug resistance. In European journal of pharmacology, 997, 177596. doi:10.1016/j.ejphar.2025.177596. https://pubmed.ncbi.nlm.nih.gov/40194645/
2. Yang, Shao-Hua, Hu, Sheng, Kang, Qiang, Zou, Hao, Zhang, Xiao-Wen. 2022. EIF5A2 promotes proliferation and invasion of intrahepatic cholangiocarcinoma cells. In Clinics and research in hepatology and gastroenterology, 46, 101991. doi:10.1016/j.clinre.2022.101991. https://pubmed.ncbi.nlm.nih.gov/35792239/
3. Wang, Kun, Wang, Yiyang, Wang, Yuanjian, Zhang, Tianli, Yang, Xingsheng. 2021. EIF5A2 enhances stemness of epithelial ovarian cancer cells via a E2F1/KLF4 axis. In Stem cell research & therapy, 12, 186. doi:10.1186/s13287-021-02256-2. https://pubmed.ncbi.nlm.nih.gov/33726845/
4. Shen, Xin, Li, Lingxia, He, Yuanyuan, Lv, Xiaohui, Ma, Jiajia. 2022. EIF5A2 Is Involved in the Biological Process of Cervical Cancer Cells through AGR2. In Pharmacology, 107, 376-385. doi:10.1159/000524017. https://pubmed.ncbi.nlm.nih.gov/35640539/
5. Yang, Jinsong, Jiang, Xue, Chen, Ying, Teng, Lisong. . EIF5A2 Promotes Doxorubicin Resistance in Bladder Cancer Cells through the TGF-β Signaling Pathway. In Discovery medicine, 35, 1167-1176. doi:10.24976/Discov.Med.202335179.113. https://pubmed.ncbi.nlm.nih.gov/38058082/
6. Zhao, Guannan, Zhang, Wenjing, Dong, Peixin, Tigyi, Gabor, Yue, Junming. 2021. EIF5A2 controls ovarian tumor growth and metastasis by promoting epithelial to mesenchymal transition via the TGFβ pathway. In Cell & bioscience, 11, 70. doi:10.1186/s13578-021-00578-5. https://pubmed.ncbi.nlm.nih.gov/33827661/
7. Gao, Jinbo, Li, Peng. 2023. Targeting eIF5A2 reduces invasion and reverses chemoresistance in SCC-9 cells in vitro. In Histology and histopathology, 39, 463-470. doi:10.14670/HH-18-637. https://pubmed.ncbi.nlm.nih.gov/37334930/
8. Hao, Fengyun, Zhu, Qingli, Lu, Lingwei, Jiao, Xuelong, Chen, Dong. 2020. EIF5A2 Is Highly Expressed in Anaplastic Thyroid Carcinoma and Is Associated With Tumor Growth by Modulating TGF- Signals. In Oncology research, 28, 345-355. doi:10.3727/096504020X15834065061807. https://pubmed.ncbi.nlm.nih.gov/32138807/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
